Truist Securities increased its price target on Centene (NYSE: CNC) to $49 from $47 while maintaining a Buy rating, citing constructive discussions with management and improving margin prospects across segments.
The firm highlighted expected Marketplace margin expansion in 2026 and anticipated progress in Medicaid during the second half of 2025, supported by initiatives designed to stabilize the health benefits ratio in 2026. Medicare Advantage remains on track toward breakeven, while 2026 Part D margins are assumed to remain prudent.
Truist stated it continues to see meaningful opportunities to unlock earnings power across Centene’s business and reiterated its positive outlook on the stock.
